TrialOncotarget2017

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.

Jie Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.